Similarly, the JVDF trial—a non-randomized, multicohort, open-label, phase 1a/b study—evaluated the combination of the anti-VEGFR2 agent ramucirumab with the anti-PD-1 therapy pembrolizumab in NSCLC and gastric cancer (GC), revealing a significant improvement in OS compared to chemotherapy. The gene discussed is KDR; the disease is gastric cancer.